Document:

EXHIBIT 10.2

 

SUBSCRIPTION
AGREEMENT

 

BY
AND BETWEEN

 

CARDAX,
INC.

 

AND

 

THE
PURCHASERS PARTY HERETO

 

DATED
AS OF __________ ___, 2015

 

    	 

    	 

    

 

TABLE
OF CONTENTS

 

	 	 	Page
	 	 	 
	ARTICLE I	DEFINITIONS	1
	1.1	Definitions	1
	ARTICLE II	PURCHASE AND
    SALE	3
	2.1	Closing	3
	2.2	Deliveries	4
	2.3	Closing Conditions	4
	ARTICLE III	REPRESENTATIONS
    AND WARRANTIES	5
	3.1	Representations
    and Warranties of the Company	5
	3.2	Representations
    and Warranties of the Purchasers	6
	ARTICLE IV	OTHER AGREEMENTS
    OF THE PARTIES	8
	4.1	Transfer Restrictions	8
	4.2	Non-Public Information	10
	4.3	Equal Treatment
    of Purchasers	10
	4.4	Use of Proceeds	10
	4.5	Form D; Blue
    Sky Filings	10
	4.6	Replacement of
    Certificates	11
	4.7	Registration
    Rights Agreement	11
	4.8	Most Favored
    Nation or Anti-Dilution Right	11
	ARTICLE V	MISCELLANEOUS	12
	5.1	Fees and Expenses	12
	5.2	Entire Agreement	12
	5.3	Notices	12
	5.4	Amendments; Waivers	13
	5.5	Headings	13
	5.6	Successors and
    Assigns	13
	5.7	Third-Party Beneficiaries	13
	5.8	Governing Law;
    Exclusive Jurisdiction	13
	5.9	Attorney Fees	14
	5.1	Survival	14
	5.11	Counterparts
    and Execution	14
	5.12	Severability	14
	5.13	Independent Nature
    of Purchasers’ Obligations and Rights	15
	5.14	Saturdays, Sundays,
    Holidays, etc	15
	5.15	Construction	15
	5.16	WAIVER OF JURY
    TRIAL	15

 

    	i

    	 

    

 

Schedules:

 

	Schedule A	 	Wire Transfer Instructions
    and Unit Price Payment Information
	 	 	 
	Schedule B	 	Supplement of Certain Risk Factors
    
	 	 	 
	Schedule C	 	Certain Matters Regarding the Plan
    of Distribution of the Offering of the Units
	 	 	 
	Exhibits:	 	 
	 	 	 
	Exhibit I	 	Form of the Class D Warrant
	 	 	 
	Exhibit II	 	Form of the Class E Warrant
	 	 	 
	Exhibit II	 	Form of the Registration Rights Agreement

 

    	ii

    	 

    

 

SUBSCRIPTION
AGREEMENT

 

This
Subscription Agreement (this “Agreement”) is dated as of the date set forth on the signature page hereof, by
and among Cardax, Inc., a Delaware corporation (the “Company”), and each Person that is a Purchaser under the
terms of this Agreement. Certain capitalized terms used in this Agreement are defined in Section 1.1.

 

WHEREAS,
the Company is a public company with its shares of common stock, par value $0.001 per share (“Common Stock”)
traded on the OTCQB under the symbol “CDXI”.

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act, and Rule
506 promulgated thereunder, the Company desires to sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase Units (each, a “Unit”), where each Unit has: (i) one share of Common Stock; (ii) two Class D Warrants
(each, a “Class D Warrant”), each Class D Warrant entitling the Purchaser of a Unit to purchase one share of
Common Stock at a price per share of $0.10, subject to certain adjustment as more fully described in this Agreement in the form
attached to this Agreement as Exhibit I; and (iii) one Class E Warrant entitling the Purchaser of a Unit to purchase
three quarters (0.75) of one share of Common Stock at a price per share of $0.1667, subject to certain adjustment as more fully
described in this Agreement in the form attached to this Agreement as Exhibit II (each, a “Class E Warrant”
and, together with a Class D Warrant, each, a “Warrant” and, collectively, the “Warrants”).

 

WHEREAS,
this Agreement and the offering of the Units by the Company are part of an offering of an aggregate amount that is up to $3,500,000
(or such greater amount as may be determined by the Company) and that in such offering there will be purchases and sales of units
that are similar to the Units purchased under this Agreement by the Purchaser on similar terms and conditions; provided, however,
the Company reserves the right to suspend or terminate any additional purchases and sales of such similar units and to change
the terms and conditions with respect to the offering of any such units or other securities by or on behalf of the Company;

 

WHEREAS,
the purchase price for each Unit (“Unit Price”) shall be $0.30.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, each of the Company and the Purchasers, intending to be legally bound
hereby, hereby agree as follows:

 

ARTICLE
I

DEFINITIONS

 

1.1 Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:

 

    	1

    	 

    

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

“Closing”
means the closing of the purchase and sale of the Units pursuant to Section 2.1.

 

“Closing
Date” means the Trading Day on which the Purchasers purchase the Units under the terms of this Agreement, including
payment to the Company of the Purchase Price payable by each of the Purchasers.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” shall have the meaning ascribed to such term in the recitals to this Agreement.

 

“Company
Counsel” means Herrick, Feinstein LLP, 2 Park Avenue, New York, NY 10016.

 

“Company
Sub” means Cardax Pharma, Inc., a Delaware corporation and a wholly owned subsidiary of the Company.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Execution
Date Information” shall have the meaning ascribed to such term in Section 3.2(f).

 

“Offering”
means this offering of the Units.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Purchaser”
means a Person that is a party to this Agreement as a purchaser, or his, her or its successors and assigns.

 

“Securities”
means all Units, Common Stock, Warrants, and shares of the Company’s Common Stock, into which the Warrants are exercisable.

 

    	2

    	 

    

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Shares”
means newly issued shares of the Company’s Common Stock, issued or issuable to each Purchaser pursuant to the exercise of
the Warrant, which shares, when issued in accordance with the terms of such securities, shall be duly authorized, validly issued,
fully paid and non-assessable.

 

“Short
Sale” means any securities transaction in which a Person sells a number of shares or other units of a security that
are not owned by such Person at the time of such sale.

 

“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for Units purchased hereunder which shall equal
the number of Units to be purchased by such Purchaser multiplied by the Unit Price in United States dollars, which amount shall
be paid by the Purchaser making a payment to the Company as provided in this Agreement.

 

“Subsidiary”
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Company’s Common Stock is listed or quoted
for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the New York Stock Exchange, OTCQB or the OTC Bulletin Board (or any successors to any of the foregoing).

 

“Transaction
Documents” means this Agreement and all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.

 

ARTICLE
II

PURCHASE AND SALE

 

2.1 Closing.

 

(a) The
Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing.

 

(b) On
the Closing Date, upon the terms and subject to the conditions set forth herein, the Company shall issue and sell to each of the
Purchasers, and each of the Purchasers, severally and not jointly, shall purchase, that number of Units that is set forth on the
signature page of such Purchaser to the extent accepted by the Company.

 

    	3

    	 

    

 

(c) Upon
satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of the
Company or such other location as the Company may designate to the Purchaser.

 

2.2 Deliveries.

 

(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser accepted by the Company, this
Agreement duly executed by the Company.

 

(b)
On the date that this Agreement is executed and delivered by a Purchaser to the Company and the Company accepts the
subscription of such Purchaser (with such acceptance to be evidenced by the Company’s counter signature of the
Purchaser’s signature page herein below), such Purchaser shall deliver or cause to be delivered to the
Company:

 

(i) a
check or wire transfer of the Subscription Amount of such Purchaser in accordance with the payment or wire transfer instructions
set forth on Schedule A to this Agreement; and

 

(ii) a
counterpart of this Agreement duly executed by such Purchaser.

 

(c) On
the Closing Date, the Company and each of the Purchasers shall close the purchase and sale of the Units and the Company shall
deliver or cause to be delivered to each Purchaser evidence of the issuance and delivery of the shares of Common Stock and Warrants
to be purchased by each Purchaser by appropriate instructions to the stock transfer agent of the Company.

 

2.3 Closing
Conditions.

 

(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i) the
accuracy in all material respects on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless such representation is made as of a specific date therein in which case such representation and warranty shall be accurate
as of such date); and

 

(ii) all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed.

 

(b) The
respective obligations of each of the Purchasers hereunder in connection with the Closing are subject to the following conditions
being met:

 

(i) The
representations and warranties made by the Company in this Agreement shall be true and correct in all material respects (provided
that any such representations and warranties that are by their terms qualified by materiality shall (as so qualified) be true
in all respects) as of the date hereof and at and as of the time of the Closing as though such representations and warranties
were made at and as of such time (except in any case that representations and warranties that expressly speak as of a specified
date or time need only be true and correct (subject to the foregoing parenthetical as to materiality) as of such specified date
or time);

 

    	4

    	 

    

 

(ii) The
Company shall have performed and complied in all material respects with all covenants and agreements required by this Agreement
to be performed or complied with by it prior to or at the Closing;

 

(iii) Without
limiting item (ii) above, the Company shall have delivered to the Purchasers each of the items required to be delivered by it
pursuant to Section 2.2(c);

 

(iv) No
preliminary or permanent injunction or other order that declares this Agreement invalid or unenforceable in any respect or that
prevents the consummation of the transactions contemplated hereby shall be in effect; and

 

(v) From
the date hereof to the Closing Date, the Commission shall not have issued a stop trading order with respect to the Company’s
Common Stock.

 

ARTICLE
III

REPRESENTATIONS AND WARRANTIES

 

3.1 Representations
and Warranties of the Company. The Company hereby makes the following representations and warranties to each Purchaser as
of the date hereof and as of the Closing Date (unless such representation is made as of a specific date therein in which case
such representation and warranty shall be accurate as of such date):

 

(a) Organization
and Qualification. Each of the Company and the Company Sub is an entity duly incorporated, validly existing and in good standing
under the laws of the jurisdiction of its incorporation, with the requisite power and authority to own and use its properties
and assets and to carry on its business as currently conducted.

 

(b) Capitalization.
The capitalization of the Company is properly reflected by the SEC Filings.

 

(c) Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Units to the Purchasers as contemplated hereby. The issuance
and sale of the Units hereunder does not contravene the rules and regulations of the Trading Market applicable to the Company.

 

(d) Disclosure.

 

(i) Except
with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information within the meaning of the
Exchange Act.

 

    	5

    	 

    

 

(ii) The
Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2.

 

(e) SEC
Filings. The documents (“SEC Filings”) that have been filed by the Company with the Securities and Exchange
Commission do not (as amended and supplemented) contain a material misstatement of fact or does not omit to state any material
fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading,
as interpreted by the Exchange Act.

 

3.2 Representations
and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants, severally
and not jointly, as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):

 

(a) Organization;
Authority.

 

(i) Such
Purchaser is either an individual or an entity that is duly incorporated or formed, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and
otherwise to carry out its obligations hereunder and thereunder.

 

(ii) The
execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the
Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar
action, as applicable, on the part of such Purchaser.

 

(iii) Each
Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in
accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against
it in accordance with its terms, except: (A) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; (B)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies; and (C)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

(b) Own
Account. Such Purchaser understands that each of the shares of Common Stock and the Warrants and the Shares are “restricted
securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring
the Units as principal for its own account and not with a view to or for distributing or reselling such Units (or the shares of
Common Stock or Warrants or Shares) or any part thereof in violation of the Securities Act or any applicable state securities
law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state
securities law and has no direct or indirect arrangement or understandings with any other person to distribute or regarding the
distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation
and warranty not limiting such Purchaser’s right to sell the Securities in compliance with applicable federal and state
securities laws). Such Purchaser is acquiring the Units hereunder in the ordinary course of its business or investment strategy.

 

    	6

    	 

    

 

(c) Purchaser
Status. At the time such Purchaser was offered the Units, it was, and as of the date hereof it is an “accredited investor”
as defined in Rule 501 under the Securities Act; or (ii) a Non U.S. Person within the meaning of Regulation S under the Securities
Act.

 

(d) Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the shares of Common Stock or Warrants (and the Shares), and has so evaluated the merits and risks of such investment. Such
Purchaser is able to bear the economic risk of an investment in the shares of Common Stock, the Warrants and Shares and, at the
present time, is able to afford a complete loss of such investment.

 

(e) Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser shall not
directly or indirectly, nor shall any Person acting on behalf of or pursuant to any understanding with such Purchaser, execute
any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of date of this
Agreement and the Closing Date. Notwithstanding the foregoing, the limitation set forth in this Section 3.2(e) shall not
be applicable to any investments of a Purchaser that are made or disposed of without the discretion of such Purchaser. Other than
to other Persons party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection
with this transaction and shall use the information provided in this Agreement or any investment presentation provided to such
Purchaser only in consideration of making an investment in the Units.

 

(f) Disclosure.

 

(i) Each
Purchaser acknowledges and agrees that the information provided and available to the Purchaser at the time that this Agreement
is executed and delivered (including, but not limited to the SEC Filings) (the “Execution Date Information”)
may not include all of the material information that would be provided to a purchaser of securities in an offering of securities
that is registered under the Securities Act and included in a prospectus that is required to be delivered in accordance with Section
5 of the Securities Act.

 

(ii) Each
Purchaser agrees that it has had an unrestricted opportunity to: (a) obtain additional information concerning the offering of
the Units, including without limitation, information concerning the Company and any other matters relating directly or indirectly
to the purchase of the Units by such Purchaser; and (b) ask questions of, and receive answers from, the executives of the Company
concerning the terms and conditions of this offering of Units and to obtain such additional information as may have been necessary
to verify the accuracy of the information contained in the investor presentation provided to the Purchaser or any other information
that may have been provided to the Purchaser.

 

    	7

    	 

    

 

(iii) Each
Purchaser acknowledges and agrees that no Person is authorized by the Company and no Person will be authorized by the Company
or any of its Affiliates to provide any information regarding the solicitation of investment interest or the offering of the Units
other than the information that is provided in the investor presentation provided by the Company and such other information or
documentation that is provided expressly by the Company to the Purchasers for such purposes.

 

(iv) Each
Purchaser and/or Purchaser’s advisor acknowledges that it has received and reviewed the SEC Filings, including the summary
of risks contained in the “Risk Factors” sections in such documents and Schedule B and certain matters regarding
the plan of distribution of the offering of the Units set forth in Schedule C and had access to or been furnished with
sufficient facts and information to evaluate an investment in the Company and a reasonable opportunity to ask questions of and
receive answers from a person or persons acting on behalf of the Company concerning the Company and all such questions have been
answered to the full satisfaction of the Purchaser.

 

(g) Due
diligence. Each Purchaser acknowledges and agrees that it has: (A) carefully reviewed the investor presentation; (B) performed
its own due diligence investigation and has been furnished with other materials that it considers relevant to the purchase of
the Units; and (C) is not relying upon, and has not relied upon, any statement, representation or warranty made by any person,
except for the statements, representations and warranties contained in this Agreement.

 

The
Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such
Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transaction contemplated hereby.

 

ARTICLE
IV

OTHER AGREEMENTS OF THE PARTIES

 

4.1 Transfer
Restrictions.

 

(a) The
shares of Common Stock, the Warrants and Shares may only be disposed of in compliance with state and federal securities laws.
After the Final Closing Date, the Company agrees to take appropriate action to promptly prepare and file a registration statement
with the SEC to register the Shares under the Securities Act, it being acknowledged that there is no assurance that all of the
Shares will be included in a registration statement that is declared effective under the Securities Act. In connection with any
transfer of any of shares of Common Stock or Warrants or Shares other than pursuant to an effective registration statement or
Rule 144, to the Company or to an Affiliate of a Purchaser, the Company may require the transferor thereof to provide to the Company
an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
shares of Common Stock or Warrants or Shares under the Securities Act.

 

    	8

    	 

    

 

(b) Legend
on Share Certificates. The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend
on any of the certificates representing the shares of Common Stock or Warrants or Shares in the following form:

 

THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE CORPORATION. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED
IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

(c) The
legends set forth in Section 4.1(b) shall, to the fullest extent permitted, be removed , (i) while a registration statement
covering the resale of such security is effective under the Securities Act, (ii) following any sale of such shares of Common Stock
or Warrants or Shares pursuant to Rule 144, (iii) if such shares of Common Stock or Warrants or Shares are eligible for sale under
Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule
144 as to such shares of Common Stock or Warrants or Shares and without volume or manner-of-sale restrictions, or (iv) if such
legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission).

 

(d) Each
Purchaser, severally and not jointly with the other Purchasers, agrees that such Purchaser will sell any shares of Common Stock
or Warrants or Shares only pursuant to either: (i) the registration requirements of the Securities Act, including any applicable
prospectus delivery requirements; or (ii) an exemption therefrom, and that if shares of Common Stock or Warrants or Shares are
sold pursuant to any such effective registration statement, they will be sold in compliance with the plan of distribution set
forth therein, and acknowledges that the removal of the restrictive legend from certificates representing shares of Common Stock
or Warrants or Shares as set forth in this Section 4.1 is predicated upon the Company’s reliance upon this understanding.

 

    	9

    	 

    

 

4.2 Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide any Purchaser
or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior
thereto such Purchaser, agent or counsel shall have entered into a written agreement with the Company regarding the confidentiality
and use of such information or such Person is otherwise obligated to maintain the confidentiality of such information and not
use such information in violation of applicable law. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in evaluating and providing any information it receives in connection with its consideration of purchasing
any of the Units.

 

4.3 Equal
Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration
is also offered to all of the Purchasers. For clarification purposes, this provision constitutes a separate right granted to each
Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase,
disposition or voting of Shares, the shares of the Company’s Common Stock issuable upon the exercise of the Warrants or
otherwise. The provisions of this Agreement do not, and in no manner shall be interpreted to, restrict the right, ability and
authority of the Company to sell any securities, including securities identical to, exchangeable for, convertible into, or similar
to, any of the securities offered and sold under this Agreement.

 

4.4 Use
of Proceeds. The Company will use the proceeds of this Offering, net of expenses described in Schedule C, for its operations.
The Company has adopted a budget that includes a 50% deferral of cash compensation payable to its Executive Chairman, Chief Executive
Officer, and Chief Science Officer; a 25% deferral of cash compensation payable to its Vice President of Operations and Vice President
of Research; and a 10% deferral of cash compensation payable to its other employees. The Company will make appropriate additional
cash compensation deferrals if substantially less funds are raised by the Company in this Offering and any other offering of securities.
The Company will not decrease such deferrals or increase the cash compensation payable to such person (other than for cost of
living increases) until at least one of the following occurs: (1) the Company raises more than $5 million in the aggregate from
this Offering and any other offerings; (2) the Company enters into a strategic partnership where the cash fees to be paid within
eighteen months of the final closing of this Offering, when combined with the proceeds from the Offering and any other offerings,
exceed $5 million; or (3) the Company has positive cash flows for any fiscal quarter.

 

4.5 Form
D; Blue Sky Filings. The Company shall timely file a Form D with respect to the Units as required under Regulation D, provide
a copy thereof, promptly upon request of any Purchaser, and take such action as the Company shall reasonably determine is necessary
in order to obtain an exemption for, or to qualify the Units for, sale to the Purchasers at the Closing under applicable securities
or “Blue Sky” laws of the states of the United States, and provide evidence of such actions promptly upon request
of any Purchaser.

 

    	10

    	 

    

 

4.6 Replacement
of Certificates. If any certificate or instrument evidencing any shares of Common Stock or Warrants or Shares is mutilated,
lost, stolen or destroyed, the Company shall cause the Company to, and the Company shall, issue or cause to be issued in exchange
and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new
certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.
The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement shares of Common Stock or Warrants or Shares and may be
required to provide an indemnity in favor of the Company.

 

4.7 Registration
Rights Agreement. The Company shall execute and deliver and shall duly perform its obligations under that certain Registration
Rights Agreement (the “Registration Rights Agreement”) in the form attached to this Agreement as Exhibit III.

 

4.8 Most
Favored Nation or Anti-Dilution Right.

 

(a) The
Company agrees to provide to the Purchaser the right (“Anti-Dilution Right”) to receive additional shares of
Common Stock and to exchange or amend its Class D Warrants for warrants that are issued by the Company to investors in an offering
(a “Qualified Financing”) that (x) has aggregate gross proceeds of $250,000 or more that (y) is received by
the Company on or prior to March 31, 2016 so that the Purchaser shall, immediately after receiving such additional shares of Common
Stock and such exchange or amendment, participate in the Qualified Financing on substantially similar terms with respect to the
average price per share of Common Stock (including the price for shares of Common Stock issuable upon the exercise of the Class
D Warrants) that an investor pays assuming the full conversion or exercise of warrants or similar rights that are issued in the
Qualified Financing. In connection with this Anti-Dilution Right, the consideration for any such additional shares of Common Stock
or exchange or amendment of the Class D Warrant shall be the Subscription Price paid by the Purchaser (and, if applicable, the
exchange of the Class D Warrant) and the Purchaser shall keep its Class E Warrant without any change, amendment or supplement.

 

(b) Prior
to the final closing of a Qualified Financing, the Company shall provide the Purchaser with a notice (the “Qualified
Financing Notice”) which shall include a copy of the offering documentation provided by the Company to solicit investment
in the Qualified Financing and describe in reasonable detail the procedures required for the Purchaser to exercise its Anti-Dilution
Right. The Purchaser may exercise its Anti-Dilution Right by providing a notice to such effect to the offices of the Company on
or prior to the date that is thirty (30) days after the date that the Purchaser received the Qualified Financing Notice. If the
Purchaser does not duly and timely exercise its Anti-Dilution Right and the Qualified Financing is consummated, then the Purchaser
shall be deemed to have waived its Anti-Dilution Right. For avoidance of doubt, the Anti-Dilution Right shall terminate on the
date that is the earlier of the date that the Purchaser does not duly and timely exercise its Anti-Dilution Right as described
in this Section 4.8 or March 31, 2016.

 

    	11

    	 

    

 

ARTICLE
V

MISCELLANEOUS

 

5.1 Fees
and Expenses.

 

(a) Except
as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement.

 

(b) Certain
disclosures regarding the Company are summarized in Schedule C, attached hereto.

 

5.2 Entire
Agreement. The Transaction Documents contain the entire understanding of the parties with respect to the subject matter hereof
and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules.

 

5.3 Notices.

 

(a) All
notices (including any consent required of any party to this Agreement) given or permitted to be provided pursuant to this Agreement
shall be in writing and shall be made by hand delivery, by facsimile, or overnight air courier guaranteeing next business day
delivery addressed as follows:

 

	 	(i)	If such notice is to the Company, then
    to the Company at
	 	 	 
	 	 	2800 Woodlawn Drive
	 	 	Suite 129
	 	 	Honolulu, Hawaii 96822
	 	 	Fax: +1 808 237 5901
	 	 	Attention: David G. Watumull
	 	 	  President & Chief Executive
    Officer

 

	 	With a copy of each notice to (which copy shall not constitute
    notice):
	 	Herrick, Feinstein LLP
	 	2 Park Avenue
	 	New York, NY 10016
	 	Attn: Richard M. Morris, Esq.
	 	Fax: (212) 545-3371

 

(ii) If
such notice is to a Purchaser, then to the address of the Purchaser set forth on the signature page of such Purchaser to this
Agreement.

 

    	12

    	 

    

 

(b) Change
of Address. Any Purchaser may change the address that notices should be delivered to it by delivering a notice with the corrected
information to the Company. The Company may change the address that notices should be delivered to it by delivering a notice with
the corrected information to each Purchaser then a party to this Agreement. In each case, such corrected information to be effective
only upon delivery of such notice.

 

(c) Deemed
Delivery. Except as otherwise expressly provided in this Agreement, each such notice shall be deemed given, delivered and
received at the time delivered by hand, if personally delivered; when receipt acknowledged, if telecopied; and the next business
day after timely delivery to the courier, if sent by overnight air courier guaranteeing next business day delivery.

 

5.4 Amendments;
Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except by means of a written agreement
signed, in the case of an amendment, by the Company and each of the Purchasers subject to such waiver, modification, supplement
or amendment. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or
requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise
of any such right.

 

5.5 Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.6 Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger); except that all rights and obligations of the Company under this Agreement shall be assigned
to, and assumed by, the Company effective on Closing Date, provided that no such assignment shall relieve the Company of any of
its obligations hereunder. Any Purchaser may assign any or all of its rights under this Agreement to any Person; provided that
such assignment is approved by the Company, which approval shall not be unreasonably withheld, delayed or conditioned and such
transferee agrees in writing to be bound by the provisions of the Transaction Documents that apply to the “Purchasers”
and such transferee is able and makes the representations and warranties to the Company provided under Section 3.2.

 

5.7 Third-Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

5.8 Governing
Law; Exclusive Jurisdiction.

 

(a) All
questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof.

 

    	13

    	 

    

 

(b) Each
party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated
by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York, Borough of Manhattan.

 

(c) Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at
the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.

 

5.9 Attorney
Fees. If one or more parties shall commence an action, suit or proceeding to enforce any provision of the Transaction Documents,
then the prevailing party or parties in such action, suit or proceeding shall be reimbursed by the other party or parties to such
action, suit or proceeding for the reasonable attorneys’ fees and other costs and expenses incurred by the prevailing party
or parties with the investigation, preparation and prosecution of such action, suit or proceeding.

 

5.10 Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Units for the applicable
statute of limitations.

 

5.11 Counterparts
and Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other
party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof.

 

5.12 Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

    	14

    	 

    

 

5.13 Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereof or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented, or has had the opportunity
to be represented, by its own separate legal counsel in its review and negotiation of the Transaction Documents.

 

5.14 Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

5.15 Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto.

 

5.16 WAIVER
OF JURY TRIAL.

 

EACH
PARTY TO THIS AGREEMENT HEREBY AGREES NOT TO ELECT A TRIAL BY JURY OF ANY ISSUE TRIABLE OF RIGHT BY JURY, AND WAIVE ANY RIGHT
TO TRIAL BY JURY FULLY TO THE EXTENT THAT ANY SUCH RIGHT SHALL NOW OR HEREAFTER EXIST WITH REGARD TO THIS AGREEMENT, OR ANY CLAIM,
COUNTERCLAIM OR OTHER ACTION ARISING IN CONNECTION THEREWITH. THIS WAIVER OF RIGHT TO TRIAL BY JURY IS GIVEN KNOWINGLY AND VOLUNTARILY
BY EACH PARTY TO THIS AGREEMENT AND IS INTENDED TO ENCOMPASS INDIVIDUALLY EACH INSTANCE AND EACH ISSUE AS TO WHICH THE RIGHT TO
A TRIAL BY JURY WOULD OTHERWISE ACCRUE. EITHER PARTY TO THIS AGREEMENT IS HEREBY AUTHORIZED TO FILE A COPY OF THIS PARAGRAPH IN
ANY PROCEEDING AS CONCLUSIVE EVIDENCE OF THIS WAIVER BY THE OTHER.

 

(Remainder
of page intentionally left blank.

Next page is signature page.)

 

    	15

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

Cardax,
inc. 

 

	By:	 	 
	Name:		 
	Title:		 

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK.

SIGNATURE PAGE FOR PURCHASERS FOLLOWS.]

 

    	 

    	 

    

 

[PURCHASER
SIGNATURE PAGES TO SUBSCRIPTION AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Subscription Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	Name of Purchaser:	 

 

	Signature of Authorized Signatory of Purchaser:	 

 

	Name of Authorized Signatory:	 

 

	Title of Authorized Signatory:	 

 

	Email Address of Authorized Signatory:	 

 

	Facsimile Number of Authorized Signatory:	 

 

	Address for Notice to Purchaser: 	 
	 	 
	 	 
	 	 
	 	 

 

Address
for Delivery of Units to Purchaser (if not same as address for notice):

 

Subscription
Amount: $_________________(U.S.)

 

Number
of Units: _________________

 

Social
Security or EIN Number: _______________________

 

Bank
or Brokerage Account Information:

 

[Each
Purchaser shall also deliver the applicable tax forms such as the Form W-9 and a certificate that they are an accredited investor,
unless waived by the Company]

 

Accepted
by the Company for ___________ Units:

 

	CARDAX, INC. 	Date: _______________

 

	By:	 	 
	Name:		 
	Title:		 

 

    	 

    	 

    

 

EXHIBIT
I

 

Form
of the Class D Warrant

(Attached
Hereto)

 

    	 

    	 

    

 

EXHIBIT
II

 

Form
of the Class E Warrant

(Attached
Hereto)

 

    	 

    	 

    

 

Exhibit
III

 

Form
of the Registration Rights Agreement

(Attached
Hereto)

 

    	 

    	 

    

 

SCHEDULE
A

 

Wire
Transfer Instructions

 

Checks shall
be made payable to the order of

 

“Cardax
Pharma, Inc.”

 

Wire Transfers
shall be made in accordance with the following:

 

	 	●	Bank Name: Bank of Hawaii
	 	●	SWIFT Code: BOHIUS77
	 	●	Routing #: 121301028
	 	●	Account #: 0090-287176
	 	●	Account Name: Cardax Pharma, Inc.

 

In addition,
the following information shall be provided with each payment:

 

	Name of Purchaser:	 

 

	Address of Purchaser:	 
	 	 
	 	 
	 	 
	 	 
	 	 

 

    	 

    	 

    

 

Schedule
B

Certain
Additional Risk Factors

 

In
addition to the risk factors that are summarized in the Company’s SEC Filings, you should

 

An
investment in our Common Stock, and Warrants involves a high degree of risk. You should carefully consider the risks summarized
in the Company’s SEC Filings, together with all of the other information provided to you in this Offering, before making
an investment decision. If any of the following risks actually occur, our business, financial condition or results of operations
could suffer. In that case, the trading price of our shares of Common Stock could decline, and you may lose all or part of your
investment. You should read the section entitled “Forward-Looking Statements” included in our SEC Filings for a discussion
of what types of statements are forward-looking statements, as well as the significance of such statements.

 

The
terms of the Offering, the price for the shares of Common Stock and Warrants, including the exercise price, were not independently
valued and may not be indicative of the future price of our Common Stock. 

 

Our
board of directors determined the terms and conditions of the Offering, including the price per share for each Unit of Common
Stock and the Warrant. The price per Unit and the exercise price were not necessarily determined to be equal to the market price
of the Company’s Common Stock on the OTCQB or the fair value of the Company. If you purchase Units in the Offering, you
may not be able to sell any of the securities at or above the subscription price. The trading price of the Company’s Common
Stock will be determined by the marketplace, and will be influenced by many factors outside of the Company’s control, including
consumer acceptance of the Company’s astaxanthin consumer health products, prevailing interest rates, investor perceptions,
securities analyst research reports and general industry, geopolitical and economic conditions. Publicly traded stocks, including
stocks of pharmaceutical and nutraceutical companies, often experience substantial market price volatility. These market fluctuations
might not be related to the operating performance of particular companies whose shares are traded. Accordingly, we cannot assure
you that if you purchase Units in the Offering you will later be able to sell those Units at or above the subscription price.

 

The
Securities are “Restricted Securities” under the Securities Act and there is no assurance that they will be registered

 

The
Units sold in this Offering and the Common Stock issuable upon exercise of the Warrants will be restricted securities under United
States federal and applicable state securities laws. The Common Stock will be restricted securities unless and until the shares
of Common Stock are registered as contemplated by the terms of the Registration Rights Agreement. Restricted securities may not
be transferred, sold or otherwise disposed of in the United States, except as permitted under United States federal and state
securities laws, pursuant to registration or an exemption therefrom. You should be prepared to hold the Securities sold and the
Common Stock issuable upon the exercise of the Warrants for an indefinite period.

 

None
of the Shares of Common Stock issued in the Offering or upon the exercise of the Warrants may be sold unless, at the time of such
intended sale, there is a current registration statement covering the resale of the securities or there exists an exemption from
registration under the Securities Act, and such securities have been registered, qualified, or deemed to be exempt under applicable
securities or “blue sky” laws in the state of residence of the seller or in the state where sales are being affected.

 

    	Schedule B | Page 1

    	 

    

 

Investors
have been provided with certain registration rights with regards to the underlying shares, however, no assurance can be given
when, if ever, such proposed registration of the underlying shares will be declared effective by the SEC or if such proposed registration
statement is declared effective that all of the shares of Common Stock sold in the Offering and underlying the Warrants will be
included in such registration statement and be permitted to be offered on a delayed or continuous basis. If the SEC does not declare
effective a registration statement covering the resale of the Shares, investors will be precluded from disposing of such Shares
unless such Shares may become eligible to be disposed of under the exemptions provided by Rule 144 under the Securities Act without
restriction. If the Shares are not registered for resale under the Securities Act, or exempt therefrom, and registered or qualified
under applicable securities or “blue sky” laws, or deemed exempt therefrom, the value of the Securities will be greatly
reduced.

 

Investors
will be relying on management’s judgment regarding the use of proceeds from this Offering and we may apply the proceeds
to uses that may not increase the value of your investment or improve our operating results.

 

We
expect to use the proceeds of this Offering to further develop our technology and infrastructure, hire additional personnel, including
management-level employees, begin focused and targeted marketing efforts, and for general working capital purposes. Our management
will have broad discretion with respect to the use of the net proceeds from this Offering and investors will be relying on the
judgment of our management regarding the application of these proceeds. We cannot assure you that the net proceeds will be used
for purposes that ultimately increase our results of operations, business prospects or the value of your investment.

 

An
investment in the Company is speculative and there can be no assurance of any return on any such investment.

 

An
investment in the company is speculative and there is no assurance that investors will obtain any return on their investment.
Investors will be subject to substantial risks involved in an investment in the Company, including the risk of losing their entire
investment.

 

Insufficient
Capital

 

While
there is a condition to closing that the Company must have subscriptions of at least $25,000 before it can close on any subscriptions
for this Offering (including amounts funded in any prior closings), there can be no assurance or guarantee that the Company will
raise sufficient capital, through this Offering, to meet the Company’s business objectives. The audited financial statements
include a going concern qualification and the Company has significant liquidity issues. The Company has adopted an austerity budget
and would need $3 million in this Offering or other capital transactions to fund its operations as contemplated in the Use of
Proceeds for one year. There can be no assurance that other obligations that are necessary for the Company will not be incurred
or that the budgeted expenditures will not be subject to any material increase.

 

Because
this Offering provides for separate closings, there cannot be any assurance that the Company would be able to raise sufficient
capital to fund its annual budget.

 

*****

 

    	Schedule B | Page 2

    	 

    

 

Schedule
C

Plan
of Distribution

 

PLAN
OF PLACEMENT

 

The
Company seeks to raise up to $3,500,000 through the offering of units (“Units”) consisting of: (i) one share
of Common Stock; (ii) two Class D Warrants, each to purchase one share of Common Stock at a price per share of $0.10; and (iii)
one Class E Warrant to purchase three quarters (0.75) of one share of Common Stock at a price per share of $0.1667. The price
per Unit (“Unit Price”) is $0.30. 

 

The
Offering of the units will be by the Company and through one or more placement agents or registered broker-dealers. Any such person
will be paid certain fees, costs and expenses required under the applicable placement agent or similar agreement from the gross
proceeds of the Offering.

 

The
Company may retain Vertical Trading Group, LLC d/b/a The Vertical Group (“Vertical”), a registered broker dealer,
as a non-exclusive placement agent in the Offering. Vertical would receive:

 

	 	●	a cash fee that is equal to 8% of the
gross proceeds invested by purchasers of the units that were introduced by Vertical to us and who were not either (x) current
or prior investors in the Company or Cardax Pharmaceuticals, Inc. or (y) previously introduced to the Company by any other placement
agent or broker-dealer that has an agreement with the Company (the “Introduced Investors”); and
	 	 	 
	 	●	warrants for the purchase of 8% of
    the aggregate number of shares of common stock sold to Introduced Investors, including shares of common stock that may be
    purchased by Introduced Investors by the exercising the warrants included in the units (“Agent Warrants”). The
    Agent Warrants grant Vertical the right to purchase our shares of common stock at a price per share equal to $0.167 and may
    be exercised on a “cashless exercise” basis and the same anti-dilution protections that are provided in the warrants
    granted with a unit.

 

Vertical
may compensate participating broker/dealers, including its affiliates, in its discretion, from fees paid to it.

 

There
can be no assurance that any or all of the Units being offered will be sold. In the event this Offering is cancelled or a subscription
is rejected, all funds received by the Company shall be returned to each Investor without interest or penalty. The Shares are
being offered solely to Accredited Investors (as such term is defined in Rule 501 promulgated under the Act) and this Offering
is being conducted in a manner intended to comply with Rule 506(b) of Regulation D promulgated by the Securities and Exchange
Commission; provided that the Company may offer its securities under any other exemption from the registration requirements of
the Act, including Regulation S.

 

The
Company’s officers, directors and employees, as well as officers, directors and employees of Vertical or any other placement
agent, may purchase Units.

 

    	Schedule C | Page 1

    	 

    

 

The
Company reserves the right to accept or reject any subscription in its sole discretion for any reason whatsoever and to withdraw
this Offering at any time prior to acceptance of the subscriptions received. Subscription funds paid by a Subscriber whose subscription
is rejected will be returned promptly without interest or deduction. Closings will be held from time to time as determined by
the Company.

 

The
minimum subscription for this offering is $25,000, though the Company may accept subscriptions in smaller amounts, in its sole
discretion. 

 

The
Company will pay all legal and other expenses and costs related to this Offering from the gross proceeds of this Offering. The
Company will also pay cash and other compensation to any broker / dealer that is entitled to such compensation under any existing
placement agent agreement, or any similar agreement, with respect to persons that were introduced by such broker / dealer to the
Company, to the extent required under such agreements. Such agreements are included as exhibits in the SEC Filings of the Company
and provide, generally, for cash compensation of 10% and issuance of warrants equal to 10% to 15% of the shares that are issued.

 

*****

 

    	Schedule C | Page 2EXHIBIT 10.3

 

WARRANT
NUMBER

D _______________

 

CARDAX,
INC.

 

WARRANT
TO PURCHASE SHARES OF COMMON STOCK 

 

NEITHER
THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER EITHER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, OFFERED FOR
SALE, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT WITH RESPECT TO SUCH
SECURITIES UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED.

 

THIS
CERTIFIES THAT, for value received, ________________________________ (together with its successors and assigns, the “Holder”),
commencing _____________ (the “Date of Issue”) is entitled to purchase, subject to the conditions set
forth below, at any time and from time to time, in whole or in part, during the Exercise Period (as defined in Section 1.3),
that number of fully paid and non-assessable shares (the “Shares”) of common stock, par value $0.001
per share (“Common Stock”), of Cardax, Inc., a Delaware corporation (the “Company”),
that is not more than the Warrant Share Number (as defined in Section 1.1), subject to the further provisions of this warrant
to purchase newly issued shares of Common Stock (the “Warrant”), at the Warrant Exercise Price (as defined
in Section 1.2), subject to the further provisions of this Warrant.

 

	1.	EXERCISE
                                         OF WARRANT

 

The
terms and conditions upon which this Warrant may be exercised, and the shares of Common Stock covered hereby which may be purchased
hereunder, are as follows:

 

1.1.Warrant.

 

(a)The
Company hereby issues to the Holder this Warrant.

 

    	 

    	 

    

 

(b)The
number of Shares that the Holder is entitled to purchase under the terms and conditions of this Warrant (the “Warrant
Share Number”) is equal to one (1) Share for each Warrant.

 

(c)
For the purposes of this Agreement, the following terms shall have the respective meanings ascribed thereto in this Section
1.1(c):

 

(i)“Affiliate”
shall have the meaning ascribed to such term under the Securities Act and the regulations promulgated thereunder.

 

(ii)“Business
Day” shall mean any date that the banks and the securities markets are in New York, New York open for business for
the conduct of business in the regular course on such date.

 

(iii)“Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended.

 

(iv)“Person”
shall mean any individual, trust or entity or governmental authority or agency.

 

1.2.The
Warrant Exercise Price. The exercise price for the Warrant (the “Warrant Exercise Price”) shall
be equal, per share, to $0.10, subject to adjustment as provided in Section 4:

 

1.3.Method
of Exercise.

 

(a)The
Holder of this Warrant may exercise, in whole or in part, the purchase rights evidenced by this Warrant during the period commencing
on the Date of Issue of this Warrant and ending on March 31, 2020, unless extended by the Company in its sole discretion (the
“Exercise Period”). Such exercise shall be effected by:

 

(i)the
surrender of the Warrant, together with a duly executed copy of the form of subscription attached hereto (a “Notice
of Exercise”), to the Secretary of the Company at its principal offices;

 

(ii)the
payment to the Company, by certified check or bank draft payable to its order, of an amount equal to the aggregate Warrant Exercise
Price for the number of Shares for which the purchase rights hereunder are being exercised; and

 

(iii)the
delivery to the Company, if necessary, to assure compliance with federal and state securities laws, of an instrument executed
by the Holder certifying that the Shares are being acquired for the sole account of the Holder and not with a view to any resale
or distribution.

 

    	2

    	 

    

 

(b)Conditions
to Exercise of the Warrant.

 

(i)Notwithstanding
the provisions of any provision of this Warrant, including Section 1.3, the exercise of this Warrant is contingent upon
the Company’s satisfaction that the issuance of the Shares for which this Warrant is being exercised is exempt from the
requirements of the Securities Act and all applicable state securities laws or the Shares are duly registered under the Securities
Act. The Holder of this Warrant agrees to execute any and all documents deemed necessary by the Company to effect the exercise
of this Warrant.

 

(ii)Notwithstanding
anything to the contrary contained herein, the number of Shares that may be acquired by the Holder upon any exercise of this Warrant
(or otherwise in respect hereof) shall be limited to the extent necessary to insure that, following such exercise (or other issuance),
the total number of shares of Common Stock then beneficially owned by such Holder and its Affiliates and any other Persons whose
beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange
Act (the “Beneficial Ownership”, does not exceed 4.99% of the total number of issued and outstanding
shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise) (the “Maximum
Percentage”). For the avoidance of doubt, except as otherwise provided herein in connection with a transaction described
in Section 4.3 (a “Fundamental Transaction”), this Warrant may not be exercised in whole or in part
if the Holder’s Beneficial Ownership (as calculated herein) exceeds the Maximum Percentage prior to such exercise. For such
purposes, “Beneficial Ownership” shall be determined in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder. This provision shall not restrict the number of shares of Common Stock
which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such
Holder may receive in the event of a Fundamental Transaction of this Warrant or under any other provision of Section 4.
This restriction may not be waived except by the Holder providing a notice to the Company as provided herein. For any reason at
any time, upon the written or oral request of the Holder, the Company shall promptly confirm in writing (which may be by electronic
mail) to the Holder the number of shares of Common Stock then outstanding. To the extent that the limitation contained in this
Section 1.3(b)(ii) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned
by such Holder together with any Affiliates) and of which a portion of this Warrant is exercisable shall be in the sole discretion
of a Holder, and the submission of a Notice of Exercise shall be deemed to be each Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by such Holder together with any Affiliates) and of which portion
of this Warrant is exercisable, in each case subject to such aggregate percentage limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination other than its obligation in this Section 1.3(b)(ii) above to,
upon the Holder’s request, confirm in writing to the Holder the number of shares of Common Stock then outstanding. Notwithstanding
any provision of this Section 1.3(b)(ii) to the contrary, the limitations on the exercise of this Warrant under this Section
1.3(b)(ii) shall not be applicable from and after the date that is 61 days after the date that the Holder provides written
notice to the Company that the Holder elects to have Beneficial Ownership of the Company’s Common Stock in excess of the
Maximum Percentage, in which case such Holder shall have the right to exercise this Warrant without the limitations of this Section
1.3(b)(ii); provided, that the limitations of this Section 1.3(b)(ii) shall again be applicable to any assignee
of this Warrant until 61 days after such assignee provides such notice to the Company.

 

    	3

    	 

    

 

1.4.Issuance
of Shares. In the event the purchase rights evidenced by this Warrant are exercised in whole or in part, one or more certificates
for the purchased Shares shall be issued as soon as practicable thereafter to the Holder.

 

1.5.Partial
Exercise. If this Warrant shall have been exercised only in part, then the Company shall, at the time of delivery of the certificate
or certificates for the Shares purchased upon such exercise, also deliver to the Holder a new Warrant evidencing the remaining
outstanding unexercised balance of Shares purchasable hereunder.

 

1.6.Cancellation.
Notwithstanding anything in this Warrant to the contrary, this Warrant shall be cancelled, and shall not be exercisable, if it
is not exercised before the expiration of the Exercise Period.

 

	2.	TRANSFER
                                         RESTRICTIONS

 

2.1.Transfer.
This Warrant and the Shares issuable upon exercise hereof are “restricted securities” as such term is defined by the
rules and regulations promulgated under the Securities Act. This Warrant and the Shares issuable upon exercise hereof may only
be disposed of in compliance with state and federal securities laws. In connection with any transfer of this Warrant or the Shares
issuable upon exercise hereof, other than pursuant to an effective registration statement or Rule 144, to the Company or to an
Affiliate of a Holder, the Company may require the transferor to provide to the Company an opinion of counsel selected by the
transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of the transferred Warrant or Shares under the
Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Warrant
and the Agreement and shall have the rights and obligations of a Holder under this Warrant and the Agreement.

 

    	4

    	 

    

 

2.2.Legend.

 

(a)The
Holder agrees to the imprinting of a legend on any of the Shares issuable upon exercise hereof in the following form:

 

THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE CORPORATION. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED
IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

(b)Notwithstanding
the foregoing, certificates evidencing this Warrant or the Shares issuable upon exercise hereof shall not contain any legend (including
the legend set forth above), (i) while a registration statement covering the resale of such security is effective under the Securities
Act, (ii) following any sale of this Warrant or such Shares issuable upon exercise hereof pursuant to Rule 144, (iii) if this
Warrant or such Shares issuable upon exercise hereof are eligible for sale under Rule 144, without the requirement for the Company
to be in compliance with the current public information required under Rule 144 as to this Warrant or such Shares issuable upon
exercise hereof and without volume or manner-of-sale restrictions, or (iv) if such legend is not required under applicable requirements
of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission).

 

    	5

    	 

    

 

2.3.Sale.
The Holder agrees that the Holder will sell this Warrant or any Shares issuable upon exercise hereof only pursuant to either:
(i) the registration requirements of the Securities Act, including any applicable prospectus delivery requirements; or (ii) an
exemption therefrom, and that if this Warrant or any Shares issuable upon exercise hereof are sold pursuant to any such effective
registration statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that
the removal of the restrictive legend from certificates representing the Shares or this Warrant is predicated upon the Company’s
reliance upon this understanding.

 

	3.	Fractional
                                         Shares

 

Notwithstanding
that the number of Shares purchasable upon the exercise of this Warrant may have been adjusted pursuant to the terms hereof, the
Company shall nonetheless not be required to issue fractions of Shares upon exercise of this Warrant or to distribute certificates
that evidence fractional shares, provided that in lieu of any fraction shares, the Company shall make a cash payment to the Holder
in an amount equal to the fair market value (as determined by the Board of Directors of the Company in its reasonable good faith)
of such fractional share.

 

	4.	ANTIDILUTION
                                         PROVISIONS

 

4.1.Stock
Splits and Combinations. If the Company shall at any time subdivide or combine its outstanding shares of Common Stock, this
Warrant shall, after that subdivision or combination, evidence the right to purchase the number of shares of Common Stock that
would have been issuable as a result of that change with respect to the shares of Common Stock which were purchasable under this
Warrant immediately before that subdivision or combination. If the Company shall at any time subdivide the outstanding shares
of Common Stock, the Warrant Exercise Price then in effect immediately before that subdivision shall be proportionately decreased,
and, if the Company shall at any time combine the outstanding shares of Common Stock, the Warrant Exercise Price then in effect
immediately before that combination shall be proportionately increased. Any adjustment under this section shall become effective
at the close of business on the date the subdivision or combination becomes effective.

 

4.2.Reclassification,
Exchange And Substitution. If the Common Stock issuable upon exercise of this Warrant shall be changed into the same or a
different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise
(other than a subdivision or combination of shares provided for above), the Holder of this Warrant shall, on its exercise, be
entitled to purchase for the same aggregate consideration, in lieu of the Common Stock that the Holder would have been entitled
to purchase but for such change, a number of shares of such other class or classes of stock equivalent to the number of shares
of Common Stock that would have been subject to purchase by the Holder on exercise of this Warrant immediately before that change.

 

    	6

    	 

    

 

4.3.Reorganizations,
Mergers, Consolidations Or Sale Of Assets. If at any time there shall be a capital reorganization of the Company’s Common
Stock (other than a combination, reclassification, exchange, or subdivision of shares provided for elsewhere above) or merger
or consolidation of the Company with or into another entity, or the sale of the Company’s properties and assets as, or substantially
as, an entirety to any other person or entity, then, as a part of such reorganization, merger, consolidation or sale, lawful provision
shall be made so that the Holder of this Warrant shall thereafter be entitled to receive upon exercise of this Warrant, during
the period specified in this Warrant and upon payment of the Warrant Exercise Price then in effect, the number of shares of Common
Stock or other securities or property of the Company, or of the successor entity resulting from such merger or consolidation,
to which a holder of the Common Stock deliverable upon exercise of this Warrant would have been entitled in such capital reorganization,
merger, or consolidation or sale if this Warrant had been exercised immediately before that capital reorganization, merger, consolidation,
or sale. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall
be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder of this Warrant
after the reorganization, merger, consolidation, or sale to the end that the provisions of this Warrant (including adjustment
of the Warrant Exercise Price then in effect and number of Shares purchasable upon exercise of this Warrant) shall be applicable
after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon
exercise of this Warrant. The Company shall, within thirty (30) days after making such adjustment, give written notice (by first
class mail, postage prepaid) to the Holder of this Warrant at the address of the Holder shown on the Company’s books. That
notice shall set forth, in reasonable detail, the event requiring the adjustment and the method by which the adjustment was calculated,
and specify the Warrant Exercise Price then in effect after the adjustment and the increased or decreased number of Shares or
the other shares or property purchasable upon exercise of this Warrant. When appropriate, that notice may be given in advance
and include as part of the notice required under other provisions of this Warrant.

 

	5.	Reservation
                                         of Stock Issuable Upon Exercise.

 

The
Company shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock solely for the
purpose of effecting the exercise of this Warrant such number of its shares of Common Stock as shall from time to time be sufficient
to effect the exercise of this Warrant and if at any time the number of authorized but unissued shares of Common Stock shall not
be sufficient to effect the exercise of this Warrant, in addition to such other remedies as shall be available to the Holder of
this Warrant, the Company will use its best efforts to take such corporate action as may, in the opinion of its counsel, be necessary
to increase its authorized but un-issued shares of Common Stock to such number of shares as shall be sufficient for such purposes.

 

    	7

    	 

    

 

	6.	RIGHTS
                                         PRIOR TO EXERCISE OF WARRANT

 

6.1.This
Warrant does not entitle the Holder to any of the rights of a stockholder of the Company, including without limitation, the right
to receive dividends or other distributions, to exercise any preemptive rights, to vote, or to consent or to receive notice as
a stockholder of the Company. If, however, at any time prior to the termination of this Warrant and prior to its exercise, any
of the following events shall occur:

 

(a)the
Company shall declare any dividend payable in any securities upon its shares of Common Stock or make any distribution (other than
a regular cash dividend) to the Holders of its shares of Common Stock; or

 

(b)the
Company shall offer to the holders of its shares of Common Stock any additional Warrant of Common Stock or securities convertible
into or exchangeable for shares of Common Stock or any right to subscribe for or purchase any thereof; or

 

(c)a
dissolution, liquidation or winding up of the Company (other than in connection with a consolidation, merger, sale, transfer or
lease of all or substantially all of its property, assets and business as an entirety) shall be proposed and action by the Company
with respect thereto has been approved by the Company’s Board of Directors;

 

then
in any one or more of said events the Company shall give notice in writing of such event to the Holder at the last address of
the Holder as it shall appear on the Company’s records at least twenty (20) days prior to the date fixed as a record date
or the date of closing the transfer books for the determination of the stockholders entitled to such dividends, distribution,
or subscription rights, or for the determination of stockholders entitled to vote on such proposed dissolution, liquidation or
winding up. Such notice shall specify such record date or the date of closing the transfer books, as the case may be. Failure
to publish, mail or receive such notice or any defect therein or in the publication or mailing thereof shall not affect the validity
of any action taken in connection with such dividend, distribution or subscription rights, or such proposed dissolution, liquidation
or winding up. Each person in whose name any certificate for shares of Common Stock is to be issued shall for all purposes be
deemed to have become the holder of record of such shares on the date on which this instrument was surrendered and payment of
the Warrant Exercise Price was made, irrespective of the date of delivery of such stock certificate, except that, if the date
of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to
have become the holder of such shares of Common Stock at the close of business on the next succeeding date on which the stock
transfer books are open.

 

    	8

    	 

    

  

	7.	SUCCESSORS
                                         AND ASSIGNS

 

The
terms and provisions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the Holder hereof and
their respective successors and permitted assigns.

 

	8.	LOSS
                                         OR MUTILATION

 

8.1.
Upon receipt by the Company of satisfactory evidence of the ownership of and the loss, theft, destruction, or mutilation of any
Warrant, and (i) in the case of loss, theft, or destruction, upon receipt by the Company of indemnity satisfactory to it, or (ii)
in the case of mutilation, upon receipt of such Warrant and upon surrender and cancellation of such Warrant, the Company shall
execute and deliver in lieu thereof a new Warrant representing the right to purchase an equal number of shares of Common Stock.

 

8.2.
The Holder also acknowledges that each of the Shares issuable upon the due exercise hereof will be subject to any transfer restrictions
in the Company’s Articles of Incorporation, including a right of first refusal to the Company, and the certificate or certificates
evidencing the Shares will bear a legend to this effect.

 

	9.	TERMINATION
                                         DATE

 

This
Warrant shall terminate upon the sooner of (a) the expiration of the Exercise Period; or (b) the exercise of all or any portion
of this Warrant pursuant to the terms of Section 1 hereof.

 

	10.	GOVERNING
                                         LAW

 

This
Warrant and any dispute, disagreement or issue of construction or interpretation arising hereunder whether relating to its execution,
its validity, the obligations provided herein or performance shall be governed or interpreted according to the internal laws of
the State of New York without regard to conflicts of law.

 

	11.	HEADINGS

 

The
headings and captions used in this Warrant are used only for convenience and are not to be considered in construing or interpreting
this Warrant. All references in this Warrant to sections and exhibits shall, unless otherwise provided, refer to sections hereof
and exhibits attached hereto, all of which exhibits are incorporated herein by this reference.

 

	12.	NOTICES.

 

All
notices or other communications given or made hereunder shall be in writing and shall be mailed by certified mail, delivered by
professional courier or hand, or transmitted via email or facsimile, to such party’s address as set forth in the Warrant
Register, or such other address as the Holder or the Company shall notify the other in writing as above provided. Any notice sent
in accordance with this section shall be effective on the date three days after the date of mailing or, if delivered by hand or
professional courier, or transmitted via email or facsimile with delivery receipt (or acknowledgement or confirmation which may
be by electronic means), on the date of delivery, provided, however, that notices to the Company will be effective upon receipt.

 

    	9

    	 

    

 

	13.	SEVERABILITY.

 

If
one or more provisions of this Warrant are held to be unenforceable under applicable law, such provision(s) shall be excluded
from this Warrant and the balance of this Warrant shall be interpreted as if such provision(s) were so excluded and shall be enforceable
in accordance with its terms.

 

	14.	Registration
                                         and Transfer of Warrants, etc.

 

14.1.
Warrant Register; Ownership of Warrants. Each Warrant issued by the Company shall be numbered and shall be registered in
a warrant register (the “Warrant Register”) as it is issued and transferred, which Warrant Register
shall be maintained by the Company at its principal office or, at the Company’s election and expense, by a Warrant Agent
or the Company’s transfer agent. The Company shall be entitled to treat the registered Holder of any Warrant on the Warrant
Register as the owner in fact thereof and the Holder for all purposes and shall not be bound to recognize any equitable or other
claim to or interest in such Warrant on the part of any other Person, and shall not be affected by any notice to the contrary,
except that, if and when any Warrant is properly assigned in blank, the Company may (but shall not be obligated to) treat the
bearer thereof as the owner of such Warrant for all purposes. Subject to Section 10, a Warrant, if properly assigned, may be exercised
by a new holder without a new Warrant first having been issued.

 

	15.	certain
                                         other provisions

 

15.1.
Any reference to an action or event to occur on a specified date that is not a Business Day shall be a reference to the immediately
following Business Day.

 

15.2.
Any calculations of the number of Shares to be issued upon the exercise of this Warrant, in whole or in part, shall be made by
the Company and, absent manifest error, such calculation shall be conclusive and binding.

 

15.3.
The terms and conditions of this Warrant shall not be amended, modified or supplemented other than in accordance with a written
amendment signed by the Holder and the Company that specifically provides for such amendment, modification or supplement.

 

    	10

    	 

    

 

	16.	Cooperation
                                         in the Registration of Shares.

 

The
Company shall have the right and obligation to register the Shares under the terms and conditions of that certain Registration
Rights Agreement by and among the Company the initial holder of this Warrant and the holder of other Class D Warrants. In any
such registration by the Company, the Holder shall cooperate with the Company and provide the Company with all information reasonably
requested from time to time by the Company.

 

[REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

    	11

    	 

    

 

In
Witness Whereof, the parties have executed this Warrant as of
the date first written above.

 

	 	COMPANY
	 	 	 
	 	Cardax, Inc.
	 	 	 
	 	By:	 
	 	Name:	
	 	Title:	

 

 

HOLDER

 

	 	 	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

    	 

    	 

    

 

NOTICE
OF WARRANT EXERCISE

 

To:
Cardax, Inc.

2800
Woodlawn Drive

Suite
129

Honolulu,
HI 96822

 

Gentlemen:

 

The
undersigned, __________________________________, hereby elects to purchase, pursuant to the provisions of the foregoing Warrant
held by the undersigned, ________________ shares of the common stock (“Common Stock”) of Cardax, Inc.

 

Payment
of the purchase price of __________ per Share required under such Warrant accompanies this notice.

 

The
undersigned hereby represents and warrants that the undersigned is acquiring such Common Stock for the account of the undersigned
and not for resale or with a view to distribution of such Common Stock or any part hereof; that the undersigned is fully aware
of the transfer restrictions affecting restricted securities under the pertinent securities laws and the undersigned understands
that the shares purchased hereby are restricted securities and that the certificate or certificates evidencing the same will bear
a legend to that effect.

 

By
its delivery of this Notice of Warrant Exercise, the undersigned represents and warrants to the Company that (unless indicated
below) in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares
of Common Stock (determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) permitted to be owned under
Section 1.3(b)(ii) of this Warrant to which this notice relates.

 

If
the number of shares of Common Stock purchased (and/or canceled) hereby is less than the number of shares of Common Stock covered
by the Warrant, the undersigned requests that a new Warrant representing the number of shares of Common Stock not so purchased
(or canceled) be issued and delivered as follows:

 

	ISSUE TO:	 	 
	 	(NAME
    OF HOLDER)	 
	 	 	 
	 	 	 
	 	(ADDRESS,
    INCLUDING ZIP CODE)	 
	 	 	 
	 	 	 
	 	(SOCIAL
    SECURITY OR OTHER IDENTIFYING NUMBER)
	 	 
	DELIVER TO:	 	 
	 	 	 
	 	(NAME)	 

 

    	 

    	 

    

 

NOTICE
OF WARRANT EXERCISE

Page
2

 

	 	 	 
	 	(ADDRESS,
    INCLUDING ZIP CODE)	 

 

DATED:
_________, ____.

 

	Signature:	 	 
	Name:	 	 
	Title:	 	 
	Address:	 	 
	 	 	 

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this
form and supply required information.

Do
not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [_____] all of or [_____] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

Dated:
______________, _______

 

Holder’s
Signature: _____________________________

 

Holder’s
Address: _____________________________

 

Signature
Guaranteed: ___________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]